- Anixa Biosciences (ANIX, Financial) maintains a strong financial position with $17 million in cash, no debt, and a low annual cash burn rate of $7 million.
- The CAR-T ovarian cancer program has shown promising survival data, with one patient surviving two years post-treatment.
- Breast cancer vaccine trial shows over 70% of patients developing immune responses, with Phase 1 completion expected in December 2025.
Anixa Biosciences (ANIX), a biopharmaceutical company focused on innovative cancer treatments, recently provided a comprehensive update on its progress across key clinical programs. As of 2025, the company reports a robust financial standing with $17 million in cash reserves and zero debt, supporting more than two years of operational runway, thanks to an annual burn rate of just $7 million, which is significantly lower than industry averages. This financial health is buoyed by a clean capital structure featuring 32 million shares outstanding with no warrants.
The company's CAR-T therapy program for recurrent, platinum-resistant ovarian cancer has successfully completed three dose-escalation cohorts. Notably, the program has yielded encouraging early survival outcomes, with one patient surviving two years and another over one year, defying the four-month median survival rate typical of this condition. The fourth cohort's initiation is planned for later this year, indicating continued momentum in this promising treatment path.
Additionally, Anixa's breast cancer vaccine program, developed in collaboration with Cleveland Clinic, is nearing conclusion of its Phase 1 trial. Impressively, more than 70% of participating patients have demonstrated protocol-defined immune responses. Upcoming milestones include the presentation of final Phase 1 data at the San Antonio Breast Cancer Symposium in December 2025, alongside anticipated FDA interactions for Phase 2 planning.
The breast cancer vaccine targets three specific patient groups: survivors of triple-negative breast cancer wary of recurrence, women at high genetic risk, and patients with residual disease post-treatment. These developments underscore Anixa's commitment to deploying innovative immunotherapy solutions across various cancer types, including lung, colon, and prostate cancers, potentially reshaping the oncological landscape.
